candesartan has been researched along with pioglitazone in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (45.00) | 29.6817 |
| 2010's | 10 (50.00) | 24.3611 |
| 2020's | 1 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Gust, R; Obexer, P; Salcher, S; Schoepf, AM | 1 |
| Benigni, A; Campana, M; Corna, D; Gagliardini, E; Garofano, E; Ito, T; Remuzzi, G; Rottoli, D; Tomasoni, S; Zanchi, C; Zoja, C | 1 |
| Miura, S; Oda, T; Omasu, F; Sakurai, Y; Yamada, M; Yamakami, K; Yoshizawa, N | 1 |
| Dong, YF; Kataoka, K; Kim-Mitsuyama, S; Matsuba, S; Nakamura, T; Ogawa, H; Tokutomi, Y; Yamamoto, E; Yamashita, T | 1 |
| Harata, S; Inden, Y; Kitamura, K; Murohara, T; Nattel, S; Shimano, M; Tsuji, Y; Uchikawa, T | 1 |
| Tsai, CT; Wilson, LD | 1 |
| Mano, R; Nakamoto, M; Ohya, Y; Sakima, A; Shinzato, T; Takishita, S; Yamazato, M | 1 |
| Kintscher, U; Krikov, M; Müller, S; Schefe, JH; Schmerbach, K; Thoene-Reineke, C; Unger, T; Villringer, A | 1 |
| Koh, KK; Quon, MJ | 1 |
| Haruna, Y; Kashihara, N; Kobayashi, S; Komai, N; Namikoshi, T; Sasaki, T; Satoh, M; Tomita, N | 1 |
| Dong, YF; Fukuda, M; Kataoka, K; Kim-Mitsuyama, S; Nakamura, T; Nako, H; Ogawa, H; Tokutomi, Y | 1 |
| Higashi, K; Hyodo, T; Kumagai, H; Kushiyama, T; Miura, S; Oda, T; Sakurai, Y; Suzuki, S; Yamada, M | 1 |
| Daida, H; Dohi, T; Iesaki, T; Kasai, T; Kubota, N; Miyauchi, K; Ogita, M; Tsuboi, S; Tsuruta, R; Yokoyama, T | 1 |
| Erdogdu, O; Eriksson, L; Nyström, T; Sjöholm, Å; Zhang, Q | 1 |
| Atkinson, J; Capdeville-Atkinson, C; Dupuis, F; Foulquier, S; Gatè, KM; Lartaud, I; Leroy, P; Liminana, P; Perrin-Sarrado, C | 1 |
| Hayashi, T; Isaka, T; Iuchi, H; Kayama, Y; Ohashi, K; Sakamoto, M; Sakamoto, N; Suzuki, H; Tojo, K; Utsunomiya, K; Yoshimura, M | 1 |
1 review(s) available for candesartan and pioglitazone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
19 other study(ies) available for candesartan and pioglitazone
| Article | Year |
|---|---|
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARγ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells.
Topics: Animals; Cell Death; Cell Proliferation; Chlorocebus aethiops; COS Cells; Drug Design; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; PPAR gamma; Structure-Activity Relationship; Telmisartan | 2020 |
Transcriptional regulation of nephrin gene by peroxisome proliferator-activated receptor-gamma agonist: molecular mechanism of the antiproteinuric effect of pioglitazone.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Gene Expression Regulation; Humans; Hypoglycemic Agents; Kidney Diseases; Male; Membrane Proteins; Pioglitazone; PPAR gamma; Proteinuria; Rats; Rats, Sprague-Dawley; Tetrazoles; Thiazolidinediones; Transcription, Genetic | 2006 |
Effects of pioglitazone and candesartan on renal fibrosis and the intrarenal plasmin cascade in spontaneously hypercholesterolemic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Disease Models, Animal; Fibrinolysin; Fibrosis; Hypercholesterolemia; Hypoglycemic Agents; Kidney; Macrophages; Male; Pioglitazone; Plasminogen Activator Inhibitor 1; Proteinuria; Random Allocation; Rats; Rats, Mutant Strains; Tetrazoles; Thiazolidinediones | 2007 |
Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Blood Vessels; Cardiomegaly; Cardiovascular Diseases; Drug Combinations; Drug Synergism; Endothelium, Vascular; Genetic Predisposition to Disease; Hypertension; Male; Myocardium; NADPH Oxidase 1; NADPH Oxidases; Nitric Oxide Synthase Type III; Pioglitazone; PPAR gamma; rac1 GTP-Binding Protein; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Reactive Oxygen Species; Stroke; Superoxides; Tetrazoles; Thiazolidinediones; Ventricular Remodeling | 2008 |
Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure.
Topics: Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Fibrillation; Benzimidazoles; Biphenyl Compounds; Blotting, Western; Disease Models, Animal; Electrophysiologic Techniques, Cardiac; Fibrosis; Heart Failure; Hypoglycemic Agents; Male; Pioglitazone; Rabbits; Tetrazoles; Thiazolidinediones | 2008 |
Heart failure-related atrial fibrillation: a new model for a new prevention strategy?
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Fibrillation; Benzimidazoles; Biphenyl Compounds; Blotting, Western; Disease Models, Animal; Electrophysiologic Techniques, Cardiac; Fibrosis; Heart Failure; Hypoglycemic Agents; Male; Pioglitazone; Rabbits; Tetrazoles; Thiazolidinediones | 2008 |
Pioglitazone, a thiazolidinedione derivative, attenuates left ventricular hypertrophy and fibrosis in salt-sensitive hypertension.
Topics: Animals; Benzimidazoles; Biphenyl Compounds; Blood Glucose; Fibrosis; Hypertension; Hypertrophy, Left Ventricular; Hypoglycemic Agents; Male; Matrix Metalloproteinases; Myocardium; Myocytes, Cardiac; Organ Size; Pioglitazone; Rats; Rats, Inbred Dahl; RNA, Messenger; Systole; Tetrazoles; Thiazolidinediones | 2008 |
Comparison between single and combined treatment with candesartan and pioglitazone following transient focal ischemia in rat brain.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Astrocytes; Benzimidazoles; Biphenyl Compounds; Brain; Cells, Cultured; Cerebrovascular Circulation; Disease Models, Animal; Drug Therapy, Combination; Gene Expression; Hypoglycemic Agents; Ischemic Attack, Transient; Magnetic Resonance Imaging; Male; Neurologic Examination; Pioglitazone; PPAR gamma; Rats; Rats, Wistar; Tetrazoles; Thiazolidinediones | 2008 |
Combination therapy for treatment or prevention of atherosclerosis.
Topics: Atherosclerosis; Benzimidazoles; Biphenyl Compounds; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Fenofibrate; Follow-Up Studies; Humans; Hypertension; Male; Pioglitazone; Risk Assessment; Severity of Illness Index; Tetrazoles; Thiazolidinediones; Treatment Outcome | 2008 |
Pioglitazone enhances the antihypertensive and renoprotective effects of candesartan in Zucker obese rats fed a high-protein diet.
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Dietary Proteins; Drug Synergism; Hypertension, Renal; Hypoglycemic Agents; Immunohistochemistry; Kidney; Male; Metabolic Syndrome; Obesity; Pioglitazone; Rats; Rats, Zucker; Renal Insufficiency, Chronic; Risk Factors; Tetrazoles; Thiazolidinediones | 2008 |
Potentiation by candesartan of protective effects of pioglitazone against type 2 diabetic cardiovascular and renal complications in obese mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Benzimidazoles; Biphenyl Compounds; Cyclic N-Oxides; Cytochrome b Group; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Drug Synergism; Hypoglycemic Agents; Kidney; Male; Membrane Glycoproteins; Mice; Mice, Inbred C57BL; Mice, Obese; Myocardium; NADPH Oxidase 2; NADPH Oxidases; Obesity; Oxidative Stress; Pioglitazone; Spin Labels; Superoxide Dismutase; Tetrazoles; Thiazolidinediones | 2010 |
Additive antifibrotic effects of pioglitazone and candesartan on experimental renal fibrosis in mice.
Topics: Adiponectin; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biomarkers; Biphenyl Compounds; Chemokine CCL2; Collagen Type I; Collagen Type III; Disease Models, Animal; Drug Therapy, Combination; Fibrosis; Kidney; Kidney Diseases; Macrophages; Male; Mice; Mice, Inbred C57BL; Pioglitazone; Plasminogen Activator Inhibitor 1; PPAR gamma; RNA, Messenger; Severity of Illness Index; Tetrazoles; Thiazolidinediones; Transforming Growth Factor beta; Ureteral Obstruction | 2010 |
Candesartan with pioglitazone protects against endothelial dysfunction and inflammatory responses in porcine coronary arteries implanted with sirolimus-eluting stents.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Coronary Vessels; Drug Therapy, Combination; Drug-Eluting Stents; Endothelium, Vascular; Hypoglycemic Agents; Inflammation; Pioglitazone; Protective Agents; Sirolimus; Sus scrofa; Tetrazoles; Thiazolidinediones; Treatment Outcome | 2011 |
Effects of some anti-diabetic and cardioprotective agents on proliferation and apoptosis of human coronary artery endothelial cells.
Topics: Apoptosis; Benzimidazoles; Biphenyl Compounds; Cardiotonic Agents; Cell Proliferation; Cell Survival; Cells, Cultured; Coronary Vessels; Endothelium, Vascular; Fluorobenzenes; Glucose; Humans; Hypoglycemic Agents; Insulin; Metformin; Pioglitazone; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Tetrazoles; Thiazolidinediones | 2012 |
Differential effects of short-term treatment with two AT1 receptor blockers on diameter of pial arterioles in SHR.
Topics: Angiotensin Receptor Antagonists; Animals; Arterioles; Benzimidazoles; Benzoates; Biphenyl Compounds; Brain; Cerebrovascular Circulation; Hypertension; Male; Microcirculation; Muscle, Smooth; Nitric Oxide Synthase Type III; Pia Mater; Pioglitazone; PPAR gamma; Rats; Rats, Inbred SHR; Receptor, Angiotensin, Type 1; RNA, Messenger; Telmisartan; Tetrazoles; Thiazolidinediones | 2012 |
Effects of co-administration of candesartan with pioglitazone on inflammatory parameters in hypertensive patients with type 2 diabetes mellitus: a preliminary report.
Topics: Adiponectin; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pressure; C-Reactive Protein; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Guanosine; Humans; Hypertension; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Plasminogen Activator Inhibitor 1; Prospective Studies; Tetrazoles; Thiazolidinediones; Treatment Outcome; Vascular Cell Adhesion Molecule-1 | 2013 |